More Articles Back to Article
FDA finds problems at Eli Lilly COVID-19 drug plant
FDA inspectors reportedly found serious quality control problems at Eli Lilly's plant in Branchburg, N.J., that's ramping up production of a COVID-19 antibody drug touted by President Donald Trump as a cure for the virus, according to federal documents and three sources with knowledge of the matter. Authorities discovered that data on the site's various manufacturing processes had been deleted and were not properly audited during a November inspection, according to government documents. Reuters (10/13)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!